# 2026-16443: NIH Offers Mesothelin Antibody for Cancer Treatment Licensing

2026-16443, Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-08-12 (as of 2026-08-19).

- Canonical: https://policyrisk.com/federal-register/2026-16443
- As of: 2026-08-19
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16443
- Title: Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 52064
- Published: 2026-08-12
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-19

## In one line

NIH Offers Mesothelin Antibody for Cancer Treatment Licensing

## Summary

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-16443 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/12/2026-16443/government-owned-invention-available-for-license-monoclonal-antibody-ro4-that-reacts-with-the)
- [2026-16443 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16443.pdf)

## Related
- [Previous: 2026-16442, Government Owned Invention Available for License: Human Antibodies Targeting Be…](https://policyrisk.com/federal-register/2026-16442)
- [Next: 2026-16444, Prospective Grant of an Exclusive Patent License: Development and Commercializa…](https://policyrisk.com/federal-register/2026-16444)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16443 (as of 2026-08-19).